Plain-English translation of NCT06305416 on ClinicalTrials.gov ↗ ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new version of ranibizumab, an eye injection used to treat diabetic macular edema—a serious eye condition where the center of the retina swells due to diabetes and causes vision problems. You would receive either the new medication or the standard FDA-approved version (), and researchers will compare how well each works and how safe each is.
Diabetic macular edema is a leading cause of vision loss in working-age adults with diabetes. This trial exists to see whether the new treatment works just as well as the established medication, which could eventually provide patients with more affordable treatment options.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic on day one for your first eye injection, then return for a safety check 48 hours later. You would receive two more injections four weeks apart (at weeks 4 and 8), with safety visits before each injection and 48 hours after the second and third injections. Your final visit would be at week 12, when researchers measure how well the treatment worked. In total, the study lasts about 3 months with multiple clinic visits.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Bangladesh